Search

Your search keyword '"Manzella, Livia"' showing total 6 results
Start Over Author "Manzella, Livia" Journal blood
6 results on '"Manzella, Livia"'

1. High BCR-ABL/GUSIS Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib

Author

Vigneri, Paolo, primary, Stagno, Fabio, additional, Stella, Stefania, additional, Cupri, Alessandra, additional, Forte, Stefano, additional, Massimino, Michele, additional, Antolino, Agostino, additional, Caracciolo, Clementina, additional, Nocilli, Laura, additional, Impera, Stefana, additional, Musolino, Caterina, additional, Turri, Diamante, additional, Russo, Mario, additional, Tomaselli, Carmela Anna Maria, additional, Rizzo, Michele, additional, Musso, Maurizio, additional, Morabito, Fortunato, additional, Levato, Luciano, additional, Manzella, Livia, additional, Mueller, Martin C, additional, Hochhaus, Andreas, additional, and Di Raimondo, Francesco, additional

Published
2015
Full Text
View/download PDF

2. High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib

Author

Vigneri, Paolo G, primary, Stagno, Fabio, additional, Stella, Stefania, additional, Cupri, Alessandra, additional, Forte, Stefano, additional, Massimino, Michele, additional, Antolino, Agostino, additional, Caracciolo, Clementina, additional, Nocilli, Laura, additional, Impera, Stefana, additional, Musolino, Caterina, additional, Turri, Diamante, additional, Russo, Mario, additional, Tomaselli, Carmen, additional, Rizzo, Michele, additional, Musso, Maurizio, additional, Morabito, Fortunato, additional, Levato, Luciano, additional, Manzella, Livia, additional, Muller, Martin C, additional, Hochhaus, Andreas, additional, and Di Raimondo, Francesco, additional

Published
2013
Full Text
View/download PDF

3. High BCR-ABL Levels At Diagnosis Are Associated with Unfavorable Responses to Imatinib Mesylate.

Author

Vigneri, Paolo G, primary, Stagno, Fabio, additional, Stella, Stefania, additional, Cupri, Alessandra, additional, Forte, Stefano, additional, Massimino, Michele, additional, Antolino, Agostino, additional, Caracciolo, Clementina, additional, Nocilli, Laura, additional, Impera, Stefana, additional, Musolino, Caterina, additional, Turri, Diamante, additional, Russo, Mario, additional, Tomaselli, Carmen, additional, Rizzo, Michele, additional, Musso, Maurizio, additional, Morabito, Fortunato, additional, Levato, Luciano, additional, Manzella, Livia, additional, Mueller, Martin, additional, and Raimondo, Francesco Di, additional

Published
2012
Full Text
View/download PDF

4. BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells.

Author

Massimino, Michele, primary, Manzella, Livia, additional, Stagno, Fabio, additional, Consoli, Maria Letizia, additional, Fallica, Manuela, additional, Aloisi, Alessandra, additional, Raimondo, Francesco Di, additional, Messina, Angelo, additional, and Vigneri, Paolo, additional

Published
2009
Full Text
View/download PDF

5. High BCR-ABL/GUSISLevels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib

Author

Vigneri, Paolo, Stagno, Fabio, Stella, Stefania, Cupri, Alessandra, Forte, Stefano, Massimino, Michele, Antolino, Agostino, Caracciolo, Clementina, Nocilli, Laura, Impera, Stefana, Musolino, Caterina, Turri, Diamante, Russo, Mario, Tomaselli, Carmela Anna Maria, Rizzo, Michele, Musso, Maurizio, Morabito, Fortunato, Levato, Luciano, Manzella, Livia, Mueller, Martin C, Hochhaus, Andreas, and Di Raimondo, Francesco

Published
2015
Full Text
View/download PDF

6. High BCR-ABL/GUSISLevels At Diagnosis Are Associated With Unfavorable Responses To Imatinib

Author

Vigneri, Paolo G, Stagno, Fabio, Stella, Stefania, Cupri, Alessandra, Forte, Stefano, Massimino, Michele, Antolino, Agostino, Caracciolo, Clementina, Nocilli, Laura, Impera, Stefana, Musolino, Caterina, Turri, Diamante, Russo, Mario, Tomaselli, Carmen, Rizzo, Michele, Musso, Maurizio, Morabito, Fortunato, Levato, Luciano, Manzella, Livia, Muller, Martin C, Hochhaus, Andreas, and Di Raimondo, Francesco

Abstract

The approval of three tyrosine kinase inhibitors (TKIs) for the first line treatment of Chronic Myeloid Leukemia (CML) has generated an urgent need for molecular parameters predictive of unfavorable therapeutic outcomes. Recent evidence suggests that failure to achieve early molecular responses (i.e. BCR-ABL/ABLISlevels <10% after 3 months or <1% after 6 months of TKI treatment) results in inferior rates of both overall and progression-free survival.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results